Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
FOLD

FOLD - Amicus Therapeutics Inc Stock Price, Fair Value and News

$14.28-0.01 (-0.07%)
Market Closed

42/100

FOLD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

42/100

FOLD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$12.24

Target 3M

$13.73

Target 6M

$13.21

FOLD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FOLD Price Action

Last 7 days

-0.5%

Last 30 days

0.2%

Last 90 days

60.5%

Trailing 12 Months

47.8%

FOLD RSI Chart

FOLD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FOLD Valuation

Market Cap

4.4B

Price/Earnings (Trailing)

-313.34

Price/Sales (Trailing)

7.36

EV/EBITDA

81.1

Price/Free Cashflow

454.63

FOLD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$12.24

Target 3M

$13.73

Target 6M

$13.21

FOLD Fundamentals

FOLD Revenue

Revenue (TTM)

598.7M

Rev. Growth (Yr)

19.46%

Rev. Growth (Qtr)

9.29%

FOLD Earnings

Earnings (TTM)

-14.1M

Earnings Growth (Yr)

357.19%

Earnings Growth (Qtr)

170.87%

FOLD Profitability

Operating Margin

98.02%

EBT Margin

0.83%

Return on Equity

-6.1%

Return on Assets

-1.62%

Free Cashflow Yield

0.22%

FOLD Investor Care

Shares Dilution (1Y)

3.26%

Diluted EPS (TTM)

-0.04

FOLD Alerts

  • 2 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025543.1M571.2M598.7M0
2024423.5M455.7M493.7M528.3M
2023336.8M350.6M372.4M399.4M
2022317.8M321.1M323.3M329.2M
2021266.8M281.8M293.9M305.5M
2020208.7M226.9M245.6M260.9M
2019108.6M131.4M159.6M182.2M
201849.5M63.6M73.3M91.2M
20179.1M16.3M25.0M36.9M
2016002.9M5.3M
201411.5M8.1M4.7M1.2M
201300015.0M
201223.2M29.8M24.0M18.4M
201147.2M38.6M30.0M21.4M
201000055.8M
200900064.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Amicus Therapeutics Inc

FOLD
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
 CEO
 WEBSITEhttps://amicusrx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES484

Amicus Therapeutics Inc Frequently Asked Questions

FOLD is the stock ticker symbol of Amicus Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Amicus Therapeutics Inc is 4.41 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check FOLD's fair value in chart for subscribers.

The fair value guage provides a quick view whether FOLD is over valued or under valued. Whether Amicus Therapeutics Inc is cheap or expensive depends on the assumptions which impact Amicus Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FOLD.

As of Wed Jan 28 2026, FOLD's PE ratio (Price to Earnings) is -313.34 and Price to Sales (PS) ratio is 7.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FOLD PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Amicus Therapeutics Inc has provided 0.09 (multiply by 100 for percentage) rate of return.